| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
173,744,000 |
| Market
Cap: |
990.34(M) |
| Last
Volume: |
148,509 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.88 - $15.45 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 607 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focusing on developing the treatment of GI diseases. LINZESS® (linaclotide), Co.'s commercial product, is a product in a class of GI medicines called guanylate cyclase type C agonists and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is available to adult men and women suffering from IBS-C or CIC in the U.S. and Mexico and to adult men and women suffering from IBS-C in Japan and China. Co. has partnerships with pharmaceutical companies to support the development and commercialization of linaclotide.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
17,604 |
53,676 |
53,676 |
| Total Buy Value |
$0 |
$160,420 |
$460,539 |
$460,539 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
2 |
3 |
3 |
| Total Shares Sold |
226,641 |
507,557 |
529,791 |
1,205,966 |
| Total Sell Value |
$1,459,885 |
$5,741,044 |
$5,974,538 |
$13,645,593 |
| Total People Sold |
6 |
7 |
8 |
11 |
| Total Sell Transactions |
7 |
12 |
16 |
50 |
| End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Silver Ronald |
Principal Accounting Officer |
• – – |
2021-07-20 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
63,242 |
|
- |
|
| Mccourt Thomas A |
Chief Executive Officer |
• • – |
2021-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
104,690 |
671,189 |
|
- |
|
| Kessler Marla L |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
22,766 |
70,187 |
|
- |
|
| Shepard Jay |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
22,766 |
58,323 |
|
- |
|
| Currie Mark G |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
22,766 |
593,758 |
|
- |
|
| Dreyfus Andrew |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
22,766 |
131,863 |
|
- |
|
| Owens Edward P |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
22,766 |
241,720 |
|
- |
|
| Duane Jon R |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
22,766 |
70,187 |
|
- |
|
| Mchugh Julie |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
22,766 |
148,373 |
|
- |
|
| Sarissa Capital Management Lp |
10% Owner |
– – • |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
22,766 |
61,845 |
|
- |
|
| Moukheibir Catherine |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
22,766 |
71,760 |
|
- |
|
| Olanoff Lawrence S |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
22,766 |
91,395 |
|
- |
|
| Mccourt Thomas A |
President and Interim CEO |
• – – |
2021-05-24 |
4 |
AS |
$12.25 |
$21,021 |
D/D |
(1,716) |
566,499 |
|
12% |
|
| Rickard Jason |
SVP, Chief Operating Officer |
• – – |
2021-05-24 |
4 |
AS |
$12.25 |
$6,321 |
D/D |
(516) |
362,538 |
|
12% |
|
| Shetzline Michael |
CMO, SVP & Head of Drug Devt. |
• – – |
2021-05-24 |
4 |
AS |
$12.25 |
$25,443 |
D/D |
(2,077) |
197,437 |
|
12% |
|
| Mchugh Julie |
Director |
– • – |
2021-04-20 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
125,607 |
|
- |
|
| Shetzline Michael |
CMO, SVP & Head of Drug Devt. |
• – – |
2021-03-26 |
4 |
A |
$0.00 |
$0 |
D/D |
38,655 |
199,514 |
|
- |
|
| Mccourt Thomas A |
President and Interim CEO |
• – – |
2021-03-26 |
4 |
A |
$0.00 |
$0 |
D/D |
96,638 |
568,215 |
|
- |
|
| Consylman Gina |
SVP, CFO & Treasurer |
• – – |
2021-03-26 |
4 |
A |
$0.00 |
$0 |
D/D |
56,372 |
392,616 |
|
- |
|
| Rickard Jason |
SVP, Chief Operating Officer |
• – – |
2021-03-26 |
4 |
A |
$0.00 |
$0 |
D/D |
56,372 |
363,054 |
|
- |
|
| Sarissa Capital Management Lp |
10% Owner |
– – • |
2021-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,235 |
39,079 |
|
- |
|
| Moukheibir Catherine |
Director |
– • – |
2021-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,573 |
48,994 |
|
- |
|
| Dreyfus Andrew |
Director |
– • – |
2021-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,460 |
109,097 |
|
- |
|
| Sarissa Capital Management Lp |
Director |
– • • |
2021-03-10 |
4 |
B |
$10.54 |
$790,500 |
I/I |
75,000 |
16,390,000 |
2.25 |
22% |
|
| Sarissa Capital Management Lp |
Director |
– • • |
2021-03-08 |
4 |
B |
$10.30 |
$1,545,000 |
I/I |
150,000 |
16,315,000 |
2.25 |
22% |
|
923 Records found
|
|
Page 7 of 37 |
|
|
